Skip to main content

COVID-19 Topic Center

News

News
Research findings presented at AMCP 2021 suggest that differences in patient-reported outcomes between authorized and independent generics were small and varied by therapeutic area, and market factors may be key in shaping observable switching patterns.
News
In November, the departing Trump administration unexpectedly ended the FDA program that led to a price spike for colchicine and other older drugs, saying it drove up drug costs and in some cases caused shortages. Now the FDA is considering whether and how to replace it, while advancing the Biden…
News
Patient-Reported Outcomes Measurement Information System Global Health scores had sufficient validity and reliability to assess health-related quality of life in atopic dermatitis, according to a recent study.
News
“Psoriasis prescriptions comprise a large, increasing proportion of Medicare Part D spending related to dermatology,” researchers wrote. “These increasing costs have significant implications for the health care system and affect out-of-pocket costs for patients who rely on such medications.”
News
According to study findings published online in Cancer Chemotherapy and Pharmacology, researchers identified the optimal dose of selinexor in patients with diffuse large B-cell.
News
According to a cross-sectional study, patients with non-radiographic axial spondyloarthritis at moderate risk of cardiovascular disease per the Systematic COronary Risk Evaluation (SCORE) model were reclassified as very high risk after ultrasound imaging revealed carotid plaques.
News
For the treatment of moderate-to-severe atopic dermatitis, biologics with the most robust efficacy and safety evidence are dupilumab, baricitinib, abrocitinib, and delgocitinib, according to a systematic review.
News
Many officials are concerned that Blue Shield's take over of the vaccination program will cause health care workers to waste valuable time learning new data systems and software instead of tracking down the state's most vulnerable vaccine-eligible residents.
News
“Costs likely vary substantially between institutions and practices, but our data suggest that even with an efficient, dedicated prior authorization group, costs are high,” researchers wrote.
News
An analysis of the characteristics of 308 adults with moderate-to-severe atopic dermatitis starting or switching systematic therapy provides a real-world picture of the substantial burden of the disease, observed researchers in the Journal of Dermatological Treatment.
Back to Top